Octreotide
Also called Sandostatin, SMS 201-995
No single human route established in this referenceProduct label
Research reference
Product label
Immediate-release octreotide indication-specific schedule
SC divided doses individualized by indication; carcinoid initial daily total 100–600 mcg in 2–4 doses
First 2 weeks of initial review; later amounts depend on symptoms and biomarkers
Octreotide acetate injection product label ↗When results may show
- When change was measured
- Glucose, gallbladder, thyroid, cardiac and indication-specific markers require review. The daily total is not a per-injection amount.
- When to assess
- First 2 weeks of initial review; later amounts depend on symptoms and biomarkers
- Conditions and limitations
- Specified endocrine or secretory tumor conditions. Immediate-release injection, long-acting depot and oral products are not interchangeable. No generic weekly or fixed starter is selected.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 9hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Octreotide acetate injection product labelImmediate-release injection, long-acting depot and oral products are not interchangeable. No generic weekly or fixed starter is selected.